We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Celldex Stock Up on Positive Data on New Cancer Candidate
Read MoreHide Full Article
Celldex Therapeutics, Inc. (CLDX - Free Report) presented pre-clinical data on a new candidate, CDX-1140, a fully human antibody that targets CD40 and demonstrated potent agonist activity. The data was presented at the Society for Immunotherapy of Cancer Annual Meeting. Importantly, the company said that its plans to start clinical development of the drug next year.
The company’s shares were up almost 14% on the news.
Data demonstrated that CDX-1140 binds to CD40 with high affinity and does not block CD40 ligand binding. The candidate has an unmodified IgG2 backbone and demonstrates potent agonist activity independent of Fc receptor interactions. It also showed direct anti-tumor activity in immune-deficient mice with human lymphomas.
Celldex expects CDX-1140 to be an important addition to the company’s growing immunotherapy pipeline. The company is also conducting manufacturing and Investigational New Drug application-enabling studies to support phase I dose-escalation trials.
Incyte’s earnings estimates increased from 20 cents to 62 cents for 2016 and from $1.42 to $1.66 for 2017 over the last 60 days. The company has posted a positive average beat of 431.43% over the last four quarters.
Anika’s earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company has posted a positive surprise in all of the four trailing quarters with an average beat of 33.14%. Its share price has gained 16.8% year to date.
Exelixis’ loss estimates narrowed from 71 cents to 51 cents for 2016 and from a loss of 16 cents to earnings of 4 cents for 2017 over the last 60 days. The company has posted a positive surprise thrice in the four trailing quarters with an average beat of 38.52%. Its share price has skyrocketed above 150% year to date.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Celldex Stock Up on Positive Data on New Cancer Candidate
Celldex Therapeutics, Inc. (CLDX - Free Report) presented pre-clinical data on a new candidate, CDX-1140, a fully human antibody that targets CD40 and demonstrated potent agonist activity. The data was presented at the Society for Immunotherapy of Cancer Annual Meeting. Importantly, the company said that its plans to start clinical development of the drug next year.
The company’s shares were up almost 14% on the news.
Data demonstrated that CDX-1140 binds to CD40 with high affinity and does not block CD40 ligand binding. The candidate has an unmodified IgG2 backbone and demonstrates potent agonist activity independent of Fc receptor interactions. It also showed direct anti-tumor activity in immune-deficient mice with human lymphomas.
Celldex expects CDX-1140 to be an important addition to the company’s growing immunotherapy pipeline. The company is also conducting manufacturing and Investigational New Drug application-enabling studies to support phase I dose-escalation trials.
Celldex currently has a Zacks Rank #2 (Buy).
CELLDEX THERAPT Price
CELLDEX THERAPT Price | CELLDEX THERAPT Quote
Other Stocks to Consider
A few other favorably placed stocks in the healthcare sector include Incyte Corporation (INCY - Free Report) , Anika Therapeutics (ANIK - Free Report) and Exelixis, Inc. (EXEL - Free Report) . All the three stocks carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
Incyte’s earnings estimates increased from 20 cents to 62 cents for 2016 and from $1.42 to $1.66 for 2017 over the last 60 days. The company has posted a positive average beat of 431.43% over the last four quarters.
Anika’s earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company has posted a positive surprise in all of the four trailing quarters with an average beat of 33.14%. Its share price has gained 16.8% year to date.
Exelixis’ loss estimates narrowed from 71 cents to 51 cents for 2016 and from a loss of 16 cents to earnings of 4 cents for 2017 over the last 60 days. The company has posted a positive surprise thrice in the four trailing quarters with an average beat of 38.52%. Its share price has skyrocketed above 150% year to date.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>